Literature DB >> 6851089

Pseudocholinesterase/high-density lipoprotein cholesterol ratio in serum of normal persons and of hyperlipoproteinemics.

R Jain, K M Kutty, S N Huang, K Kean.   

Abstract

The proposed complementary risk factor, pseudocholinesterase/high-density lipoprotein cholesterol ratio, was significantly higher in patients with type IIb and IV hyperlipoproteinemias then in controls. In contrast, the established risk factor, total cholesterol/high-density lipoprotein cholesterol ratio, was significantly higher in patients with type IIa and IV hyperlipoproteinemias. Discriminant analysis indicated that prediction of risk for coronary heart disease on the basis of lipoprotein phenotypes can be improved by about 20% when both the above factors are assessed concurrently. On the basis of earlier studies in humans and animals, we also suggest that the proposed risk factor may provide a better understanding of events leading to enhanced risk for coronary heart disease as a consequence of nutrition and of abnormal metabolism of lipids and lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6851089

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

1.  Abdominal Obesity Associated with Elevated Serum Butyrylcholinesterase Activity, Insulin Resistance and Reduced High Density Lipoprotein-Cholesterol Levels.

Authors:  Surapon Tangvarasittichai; Suthap Pongthaisong; Suwadee Meemark; Orathai Tangvarasittichai
Journal:  Indian J Clin Biochem       Date:  2014-06-01

2.  Change in serum cholinesterase activity in Jamaican diabetics.

Authors:  D Ragoobirsingh; B S Bharaj; E Y Morrison
Journal:  J Natl Med Assoc       Date:  1992-10       Impact factor: 1.798

3.  Relationship between serum pseudocholinesterase and triglycerides in experimentally induced diabetes mellitus in rats.

Authors:  V Annapurna; I Senciall; A J Davis; K M Kutty
Journal:  Diabetologia       Date:  1991-05       Impact factor: 10.122

4.  Plasma cholinesterase activity in patients during therapy with dexamethasone or prednisone.

Authors:  V Bradamante; E Kunec-Vajić; M Lisić; I Dobrić; I Beus
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Butyrylcholinesterase as a prognostic marker: a review of the literature.

Authors:  Lidia Santarpia; Ilenia Grandone; Franco Contaldo; Fabrizio Pasanisi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-09-06       Impact factor: 12.910

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.